What Exactly Is a Therapeutic Use Exemption (TUE)? A Guide for Cyclists on the System and Its Controversies

The anti-doping system has one problem it must face from day one, yet can never solve perfectly: athletes get sick, too.

Asthma, diabetes, inflammatory bowel disease, autoimmune conditions, endocrine disorders, ADHD, hormone replacement after cancer treatment—a significant portion of the standard treatments for these conditions fall within the scope of the Prohibited List. If the system took a zero-exception stance, the result would be: if you have certain diseases, you must choose between “treating the illness” and “remaining an athlete.”

That is clearly unreasonable. But if the system threw its doors wide open, allowing “anything goes as long as a doctor signs off,” the Prohibited List would quickly become a document in name only.

Therapeutic Use Exemption (TUE) is the mechanism the system has designed to handle this dilemma. It is the part of the entire anti-doping framework that requires the most nuanced judgment, and is also the most easily misunderstood and misread.

Let me be clear upfront: this article explains the concept and general principles of the system; it is not an application guide, nor is it any kind of medical or medication advice. For the specific criteria wording, application forms, deadlines, governing bodies, and eligible persons, always refer to the latest version of the International Standard for Therapeutic Use Exemptions (ISTUE) and the announcements of your governing organization. If you have any medical condition or medication need, consult a physician, and proactively inform them that you are an athlete who may be subject to anti-doping rules.

---

1. A TUE is not a “privilege pass,” but authorization to “return to baseline”

The most critical sentence for understanding TUE is: it authorizes treatment, not enhancement.

The system’s position is this: when an athlete’s physiological function falls below normal levels due to illness, treatment that brings them back to a “normal, healthy state” does not constitute unfairness; but if the same treatment pushes them above normal levels, that crosses the line. The entire TUE criteria framework revolves around this line.

This positioning leads to a corollary that is often overlooked: obtaining a TUE does not mean you have an advantage over others; in theory, it means you are making up for a disadvantage. But this “in theory” is very difficult to verify precisely in reality—and that is the source of all the controversy, which we will discuss in detail later.

Another common misunderstanding is treating a TUE as a “just file it in advance and you’re fine” procedure. It is not a notification; it is substantive review. Submitting an application does not equal approval, and rejections do exist. By design, reviewers look at complete clinical evidence, not just a doctor’s signature.

---

2. The four criteria: what TUE review examines

Under the International Standard for Therapeutic Use Exemptions, a TUE application must in principle satisfy four conditions simultaneously. The wording of these four conditions varies between versions, but the core concepts are quite stable:

#	Criterion (concept)	What the reviewer is actually asking	Common application weaknesses
1	Without the prohibited substance or method, the athlete would face significant health impairment	What happens if this condition goes untreated? Is there objective evidence of severity?	Unclear diagnosis, lack of objective test reports, only subjective symptom descriptions
2	The therapeutic use will not produce performance enhancement beyond returning to a “normal healthy state”	Is this dose and this route what the treatment requires, or is it more than that?	Dosage or route of administration higher than clinically necessary, treatment plan deviating from standard practice
3	There is no reasonable alternative treatment	Is there a medication not on the List that can achieve the same therapeutic goal?	No explanation of why non-prohibited alternatives cannot be used, or they were never even tried
4	The necessity for the use is not a consequence of prior use of a prohibited substance without an exemption	Was this condition caused by the athlete’s own drug use?	E.g., applying for replacement therapy after prior use of certain substances suppressed endocrine function

All four criteria must be satisfied in full. This is a fairly high threshold, and the burden of proof lies with the applicant.

The fourth criterion deserves special explanation, because it addresses a very typical loophole: if someone first violates the rules by using a certain class of substances, which suppresses their own physiological function, and then claims “I have a deficiency now, so I need treatment,” the system must be able to reject this cycle. This provision exists precisely for that purpose.

---

3. Who applies, when to apply, and to whom

This is the part that is easiest to get confused about in practice, because it depends on your level.

Jurisdiction determined by level

Athlete level	Who to apply to, usually	Notes
International-level athletes (defined by the International Federation, usually including members of the Registered Testing Pool and those competing in certain levels of international events)	The sport’s International Federation	For cycling, that is the UCI or its designated body
National-level athletes (defined by the National Anti-Doping Organization)	The National Anti-Doping Organization (NADO) of the athlete’s country	Our country also has a national-level organization responsible for this
Participants in specific major events	The Major Event Organization of that event	For example, multi-sport games may have dedicated procedures
General amateur riders, participants in non-regulated events	Usually no advance application needed	But if you enter an event with doping controls, the situation changes

The definitions of “international-level” and “national-level” are set and published by each organization. The same athlete may change jurisdictional归属 due to promotion, selection for a national team, or entering an event at a certain level. This is where mistakes most often happen: an athlete who has only competed domestically for years may, upon going abroad for their first international event, find that an exemption previously granted domestically does not automatically take effect at the international level.

The principle of advance application

In principle, a TUE should be obtained before the prohibited substance is used. The reasoning is straightforward: the system wants review to happen before the fact, not retroactive endorsement.

In practice, this means that if you belong to a level requiring advance application, and your doctor prescribes something that may fall on the List, the correct sequence is: confirm your status → apply for an exemption if needed → use the substance only after approval (except in emergencies, see below). This process takes time, so “handle it as soon as you spot the problem” is important.

Retroactive TUE

The system acknowledges that advance application is not always feasible, and therefore allows retroactive applications in specific circumstances, generally including:

• Emergency medical treatment: e.g., emergency room visits, accidental injuries, sudden illness, where it is objectively impossible to apply first
• Not enough time: where, due to timing, location, or other circumstances, it was objectively impossible to submit and complete review before use
• The rules themselves allow it: certain levels of athletes are, by regulation, on a “apply when needed” model
• Exceptional circumstances: other fairness considerations recognized under the rules

Retroactive applications must still pass the same four criteria; they are not relaxed because they are filed after the fact. What is relaxed is only the timing, not the substantive standard.

Athletes at levels not requiring advance application

This point is especially important for amateur and lower-level athletes. Many countries’ systems are designed so that: only athletes above a certain level need advance application; everyone else only needs to file a retroactive application if they are tested and receive an adverse finding.

This sounds convenient, but it has a real-world trap: you must be able to produce complete clinical evidence after the fact. If you did not keep clear diagnostic records, objective test reports, or prescriptions when you sought treatment, you may have nothing to show when the time comes to prove “I really had this condition, and I really needed this treatment.”

So “no advance application required” does not mean “nothing to do.” What you should do is: keep complete medical records.

4. How the Review Process Works

A TUE application is typically reviewed by a Therapeutic Use Exemption Committee (TUEC). The system imposes several basic requirements on this committee:

• Members must be physicians with relevant clinical experience, and a minimum number of members is usually required to avoid relying on a single judgment.
• Independence is required, avoiding conflicts of interest with the applicant.
• Confidentiality obligations apply to the application content—because the application contains detailed medical records, which are highly sensitive personal health information.
• For cases outside their area of expertise, external specialist opinions may be sought.

What applicants typically need to submit includes: a complete medical history, a clear diagnosis, objective test results supporting the diagnosis, the substance and dosage intended for use, the route of administration, the duration of treatment, and an explanation of why alternative treatments cannot be used. “My doctor says I need it” is not sufficient to constitute a valid application—the system requires clinical evidence that can be independently reviewed.

There are several possible review outcomes: approval (usually specifying the substance, dosage, and duration permitted), a request for additional information, or denial. Approvals also have a validity period; once it expires, a new application is required. Changes in the medical condition, dosage adjustments, or switching medications also typically require a new application.

Clinical Scenarios Commonly Seen in Exemption Evaluations in Practice

The following is a conceptual summary intended to help you understand “what kind of situations would require going down this path.” It is not medication guidance, nor does it mean these conditions necessarily require or will qualify for an exemption. Any individual case must be evaluated by a physician.

Clinical Scenario Category	Why It May Involve Exemption Evaluation	What the Review Typically Specifically Requires
Respiratory diseases and airway hyperresponsiveness	Some standard treatment medications fall into prohibited categories, and the route of administration affects the determination	Objective evidence from standard lung function or provocation tests
Endocrine and metabolic diseases	Hormone replacement therapy and metabolic regulation medications fall into prohibited categories	Clear diagnosis, long-term follow-up data, dosage consistent with standard alternative treatment protocols
Autoimmune and inflammatory diseases	The route of administration for some anti-inflammatory treatments is restricted	Diagnostic basis, disease activity, why alternative treatments are not feasible
Neurological and psychiatric diagnoses	Some treatment medications fall into the prohibited stimulant category	Diagnostic assessment and treatment history issued by a specialist physician
Acute trauma and post-operative care	The route of administration for some pain management and anti-inflammatory treatments is restricted	Imaging or surgical records, explanation of the urgency of the treatment
Cancer treatment and subsequent care	Treatment and supportive care may involve multiple categories of prohibited substances	Complete medical records, treatment plan, explanation from the attending physician

The purpose of this table is to help you determine “whether you should ask about your situation early.” If your condition falls into any of the categories above, and you intend to participate in events with drug testing, then “checking early with your physician and your governing association” is not an unnecessary step.

If the Application Is Denied, or If You Miss the Deadline

A denial does not mean “you have been found to be cheating.” Common reasons for denial are mostly insufficient evidence or failure to meet the criteria, such as a diagnosis lacking objective basis, failure to explain alternative treatments, or dosage exceeding standard clinical practice. The system generally allows you to resubmit with additional information, or to file an appeal as provided by the rules.

What is truly difficult is the time gap: the prescription has already been written, but the review has not yet been completed. The correct order of action in this situation is—lay the problem out in the open first, rather than deciding on your own whether to take the medication. Specifically, inform both your physician and the contact person at your governing association that “I am awaiting an exemption review,” so the physician can assess whether there is a non-prohibited alternative that can be used temporarily, or whether treatment can be briefly postponed without compromising your health. This decision must be made by the physician, not by you or your coach.

It bears repeating: if the physician determines that treatment cannot wait, then it cannot wait. Health takes priority over competition eligibility. This is not a platitude—it is the position of the system itself. TUE exists precisely so that you do not have to trade your health for eligibility.

Cross-Organization Recognition and Oversight

The same athlete may be under the jurisdiction of multiple organizations simultaneously, so the system includes a mutual recognition mechanism: under specific conditions, a TUE issued by one organization can be recognized by another, avoiding the need for athletes to apply repeatedly.

At the same time, WADA retains review authority: it can proactively or upon request review the issuance or denial of a TUE and revoke or overturn it if it is found not to meet the standards. Athletes and organizations that disagree with a decision also have avenues of appeal to appellate bodies (for international-level cases, typically the Court of Arbitration for Sport).

The purpose of this design is to prevent “TUE havens”—if any organization has clearly lax review standards, it would create a breach in the entire system. Therefore, an overarching mechanism for consistent oversight is necessary.

---

5. Map of Controversies: Why TUE Remains at the Center of the Storm

TUE is the part of the anti-doping system most prone to public misunderstanding. Below are the main controversies, with the positions of various parties presented as fairly as possible.

Controversy 1: “Legal medication use” gets read as “legal cheating” in the court of public opinion

In 2016, a large-scale leak of athletes’ medical and TUE data occurred, with application contents from athletes of multiple countries published online. This incident sparked discussion at two levels.

The first level is data security. Athletes’ medical records are highly sensitive information. If the system requires athletes to surrender this information in order to compete, it has an obligation to protect it. Following this incident, data protection became a continuously strengthened priority in international standards.

The second level is more difficult: how the public interprets it. When a single TUE record is published in isolation, most readers lack a clinical background and cannot judge whether the treatment was reasonable, whether the dosage was appropriate, or whether the criteria were met. The result is often a simplified headline like “Athlete X used prohibited substance Y,” with the full medical context discarded. An athlete who lawfully obtained an exemption and treated an illness according to the rules may thus face the same public condemnation as someone who committed a violation.

This raises a tension in the system that is difficult to resolve: between transparency (the public’s right to know how the rules are enforced) and medical privacy (athletes should not be forced to disclose their medical history), there is no balance point that satisfies everyone.

Controversy 2: The prevalence of certain conditions among endurance athletes

Among endurance athlete populations, the prevalence of exercise-induced bronchoconstriction and asthma-related symptoms is generally considered higher than in the general population. This phenomenon itself has a physiologically sound explanation: prolonged, high-ventilation breathing passes large volumes of relatively cold, dry, or irritant-laden air through the airways, and repeated stimulation can increase airway responsiveness. Winter sports and swimming (chlorine exposure) are also frequently mentioned in the literature.

But this fact is interpreted in two opposing directions in public discourse:

• One interpretation is: the high prevalence is an occupational consequence of the sport itself, and the need for treatment is genuine.
• The other interpretation is: the high prevalence raises suspicion of loose diagnostic practices—that is, “being diagnosed in order to obtain a TUE.”

The system’s response has been to raise the requirement for objective evidence: for such applications, standard lung function tests or provocation test results are typically required, and mere symptom descriptions are not accepted. This is a quite reasonable direction—replacing subjective claims with objective testing is the most effective tool for resolving this type of controversy.

It must be emphasized: “a higher prevalence of a condition in a certain group” and “these people are all exploiting loopholes” have no logical necessary connection. Equating the two is unfair to genuine patients.

Controversy 3: Criterion 2 is scientifically difficult to quantify precisely

“Must not produce additional benefit beyond returning to normal health”—this statement is conceptually clear but extremely difficult to quantify in practice.

The problem is: “What would this person’s baseline level have been if they had not been ill?” cannot be observed. You can only estimate it from their state after becoming ill and from population reference values. When a treatment brings a physiological indicator back into the “normal range,” has it returned to the individual’s personal baseline, or has it exceeded it? In many cases, existing tests cannot provide a clear answer.

The practical consequence of this limitation is: the review relies heavily on the proxy indicator of “whether the dosage and route of administration conform to standard clinical practice.” If the dosage, route, and duration all fall within the standard ranges found in textbooks, the treatment is presumed to be therapeutic; only if it clearly exceeds them is it considered problematic. This is a pragmatic but imperfect approach.

Controversy 4: The Ability to Apply Is Itself Unequal

Submitting a qualified TUE application requires: access to healthcare for a diagnosis, the ability to afford objective examinations, a physician familiar with the system to assist in drafting, the language skills to handle international applications, and the time to track the supplementary document process.

These conditions vary enormously between athletes from different countries and with different levels of resources. The result may be: athletes from resource-rich regions can legally treat their illnesses and continue competing, while athletes with the same condition from resource-poor regions either compete while ill or inadvertently violate the rules without knowing.

This is not a design flaw in the TUE system itself, but rather a projection of global resource inequality onto the anti-doping field. However, it does affect the substantive fairness of the system, and it is precisely why education, outreach, and procedural simplification continue to be emphasized.

Controversy 5: The Costs of Two Types of Failure Are Asymmetric

When designing the strictness of review, the system faces a classic trade-off:

If review is too lenient	If review is too strict
TUE becomes a legal loophole, and the prohibited list is rendered ineffective	Genuine patients are denied, forced to choose between health and sport
Harms the system’s credibility; those who follow the rules suffer	Harms individual athletes’ right to health and their careers
The cost of errors is spread across everyone and is harder to see	The cost of errors is concentrated on specific individuals, highly visible and immediate
Once exposed, public trust drops significantly	May trigger disputes over discrimination and health rights

The two types of errors differ in nature, visibility, and who bears the cost. The system can only find a position between the two, and any position will leave some people dissatisfied. Understanding this helps in viewing related news from a fairer perspective—this is not a question with a standard answer.

---

6. Common Misconceptions vs. Reality

Misconception	Reality
“A TUE is just a pass to use banned substances legally”	It authorizes treatment to restore normal health, not to gain an advantage; the four criteria are not easy to meet
“A doctor’s signature is all it takes”	It requires diagnosis, objective examinations, treatment plans, and evaluation of alternatives, substantively reviewed by an independent physician panel
“Once you get a TUE, you’re set for life”	Validity periods, permitted substances, and dosages are all limited; changes in condition or prescriptions usually require a new application
“If it’s approved domestically, it’s valid for international competitions too”	It depends on mutual recognition mechanisms and jurisdictional levels; cross-level situations may require separate handling
“Amateur athletes don’t need to worry about TUEs”	Prior approval is usually not needed for non-regulated events, but once you enter an event with doping controls, you fall within its scope
“Retroactive applications are easier”	Retroactive applications apply the same four criteria, only the timing is relaxed
“A publicly disclosed TUE record equals evidence of cheating”	A TUE is the product of a legal process; the record alone cannot determine reasonableness; the full clinical context is required
“No prior approval needed means nothing to do”	You still need to keep complete medical records; otherwise, you cannot provide evidence later

---

7. Practical Implications for Amateur Cyclists

You may never apply for a TUE in your lifetime. But the following points are useful for anyone who participates in races.

One: Know when “the situation has changed.” You might just be a weekend rider, and one day you sign up for an event with doping controls or are selected for a representative team—from that moment on, your medication use falls within the system’s scope. This turning point is easy to overlook because no one usually reminds you.

Two: Treat medical records as an asset to accumulate. Whether or not you need a TUE now, developing the habit of keeping diagnoses, test reports, prescriptions, and medication packaging costs very little. If you ever need to file a retroactive application, these are your only evidence. Taking a photo with your phone and backing it up to the cloud takes five seconds.

Three: Those with chronic conditions need to plan ahead even more. If you have asthma, diabetes, autoimmune disease, endocrine issues, or other conditions requiring long-term medication, and you intend to compete at higher levels, confirm the process with your physician and your federation early—don’t wait until a week before the entry deadline. These applications often require supplementary documents and time.

Four: Never interrupt necessary treatment out of concern for your eligibility. This is the most important point. Sporting eligibility should never take priority over your health. If your physician believes a treatment is necessary, the correct approach is to “undergo treatment while addressing the eligibility issue,” not to “stop medication for the sake of racing.” The very purpose of the TUE system is to ensure you don’t have to make that choice.

Five: Proactively disclose your athlete status before taking any medication. This point will recur throughout this series because it is the one thing entirely within your control. Adding one sentence during a clinic visit—“I compete in races and may be subject to anti-doping rules; does this medication contain anything I need to watch out for?”—costs three seconds.

---

8. Situations Requiring Immediate Medical Attention—Do Not Hesitate

This section has nothing to do with eligibility; it is purely a safety reminder. If any of the following occurs, seek medical attention immediately, and do not delay out of concern for medication eligibility:

• Chest tightness, chest pain, noticeable difficulty breathing, or altered consciousness during or after exercise
• Unexplained persistent palpitations or a sensation of arrhythmia
• Sudden severe headache, visual disturbances, unilateral weakness, or speech difficulty
• In hot environments: cessation of sweating, extreme confusion, or abnormally elevated body temperature
• Persistent fever combined with a sharp decline in exercise capacity
• Persistent pain, swelling, or limited mobility after any injury

Nothing in this article can replace professional medical evaluation. Eligibility issues can be dealt with afterward; health issues cannot.

---

Key Takeaways

1. A TUE addresses the unavoidable dilemma that “athletes are also patients”: neither forcing sick people to choose between the two, nor allowing the prohibited list to be rendered ineffective.
2. It authorizes treatment to restore normal health, not to gain an additional advantage; this line is the core of all criteria and controversies.
3. All four criteria must be met: significant health impairment without treatment, no additional performance enhancement from treatment, no reasonable alternative, and the need does not stem from prior prohibited use.
4. Jurisdiction depends on the athlete’s level (International Federation / National Anti-Doping Organization / Event Organizer), and the level can change with promotion or participation; it does not automatically carry over across levels.
5. Prior approval is the principle, but retroactive applications are possible for emergency medical situations, objective inability to apply in time, or circumstances permitted by the rules; retroactive applications apply the same criteria.
6. Review is conducted by an independent physician panel, requiring objective clinical evidence; approvals have validity periods and scope, with mutual recognition and oversight mechanisms in place.
7. Major controversies include: data leaks and public misinterpretation, debates over the prevalence of certain conditions in endurance populations, the difficulty of quantifying Criterion 2, inequality in the ability to apply, and the asymmetric costs of the two types of review errors.
8. The three most practical things for amateur athletes: keep complete medical records, watch for the turning point when “the situation changes,” and never interrupt necessary treatment due to eligibility concerns.

Finally, to reiterate: this article explains the conceptual framework of the system and does not replace official documents such as the ISTUE, nor does it constitute any medical or medication advice. For the exact wording of the criteria, application procedures, governing bodies, and deadlines, please refer to the latest announcements from WADA, the UCI, and your national anti-doping organization. For any medical or medication decisions, please consult your physician or pharmacist first, and proactively disclose your athlete status.

Related Reading

• What Does Anti-Doping Regulation Actually Govern? From the Three Criteria of the Prohibited List to What Amateur Cyclists Should Know
• How Do Doping Controls Work? A Complete Breakdown from In-Competition Sample Collection, Out-of-Competition No-Notice Testing to the Whereabouts System
• The Doping Risks Amateur Athletes Most Easily Stumble Into: Five Blind Spots in Cold Medicine, Supplement Contamination, and Traditional Chinese Medicine
• Banned Substances and Sport: The Science of Anti-Doping and How to Protect Yourself with Clean Supplements